Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study. (PubMed, Clin Ophthalmol) - Jul 14, 2022 - "Serum licaminlimab was undetectable in most patients; the maximum concentration observed was 8.47 ng/mL. Topical ocular licaminlimab demonstrated statistically significant improvement in global ocular discomfort score compared to Vehicle in patients with severe DED, with good tolerability, no increase in IOP, and minimal systemic drug exposure."
Clinical • P2 data • Diabetic Retinopathy • Dry Eye Disease • Oncology • Ophthalmology • Retinal Disorders
|